Last $163.76 USD
Change Today +0.11 / 0.07%
Volume 5.8M
AGN On Other Exchanges
Symbol
Exchange
New York
Berlin
As of 12:44 PM 04/23/14 All times are local (Market data is delayed by at least 15 minutes).

allergan inc (AGN) Snapshot

Open
$163.18
Previous Close
$163.65
Day High
$165.01
Day Low
$160.59
52 Week High
04/22/14 - $165.45
52 Week Low
06/24/13 - $81.33
Market Cap
48.9B
Average Volume 10 Days
8.2M
EPS TTM
$4.44
Shares Outstanding
299.1M
EX-Date
02/26/14
P/E TM
36.8x
Dividend
$0.20
Dividend Yield
0.12%
Current Stock Chart for ALLERGAN INC (AGN)

allergan inc (AGN) Related Businessweek News

View More BusinessWeek News

allergan inc (AGN) Details

Allergan, Inc. operates as a multi-specialty health care company primarily in the United States, Europe, Latin America, and the Asia Pacific. The company discovers, develops, and commercializes pharmaceutical, biological, medical device, and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological, and other specialty markets. It operates in two segments, Specialty Pharmaceuticals and Medical Devices. The Specialty Pharmaceuticals segment produces a range of pharmaceutical products, including ophthalmic products for dry eye, glaucoma, inflammation, infection, allergy, and retinal disease; Botox for certain therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth, and other prescription and physician-dispensed skin care products; and urologics products. The Medical Devices segment offers a range of medical devices, such as breast implants for augmentation, revision, and reconstructive surgery, as well as tissue expanders; and facial aesthetics products. The company sells its products to drug wholesalers, independent and chain drug stores, pharmacies, commercial optical chains, opticians, mass merchandisers, food stores, hospitals, group purchasing organizations, integrated direct hospital networks, ambulatory surgery centers, government purchasing agencies, and medical practitioners. It focuses on eye care professionals, neurologists, physiatrists, dermatologists, plastic and reconstructive surgeons, aesthetic specialty physicians, urologists, urogynecologists, and general practitioners. The company has collaboration agreements with Molecular Partners AG; Spectrum Pharmaceuticals, Inc.; and Serenity Pharmaceuticals, LLC. Allergan, Inc. was founded in 1948 and is headquartered in Irvine, California.

11,400 Employees
Last Reported Date: 02/25/14
Founded in 1948

allergan inc (AGN) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $1.4M
President
Total Annual Compensation: $651.9K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $641.5K
Corporate Vice President and President of Nor...
Total Annual Compensation: $550.7K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $642.1K
Compensation as of Fiscal Year 2013.

allergan inc (AGN) Key Developments

Allergan Inc., Valeant Pharmaceuticals International, Inc. - M&A Call

Allergan Inc., Valeant Pharmaceuticals International, Inc. - M&A Call

Pershing And Valeant To Take Over Allergan

Pershing Square Capital Management, L.P. and Valeant Pharmaceuticals International, Inc. (TSX:VRX) to pursue a takeover of Allergan Inc. (NYSE:AGN). Valeant currently intends to propose a merger in which the Allergan’s shareholders will receive a combination of cash and Valeant common shares. Valeant has not yet determined the amount of cash and number of Valeant common shares it will offer, but it currently expects the cash component will total around $15 billion. As per person familiar with the matter, the cash-and-stock offer will probably work out to $165 a share to $170 a share for Allergan, though the exact figure is still undecided. Barclays and Royal Bank of Canada have indicated that they are prepared to deliver financing commitments covering the cash portion of the transaction at the time Valeant makes an offer.

Pharma Companies Reportedly Mulls To Acquire ThromboGenics

Novartis AG (SWX:NOVN) and Shire plc (LSE:SHP) are among bidder, who are seeking to acquire ThromboGenics NV (ENXTBR:THR) people familiar with the matter said. Novartis is being considered the most likely buyer because it already has a partnership to market ThromboGenics’s Jetrea eye medicine, the people said, asking not to be identified because the process is private. The sale may value the company at as much as $1.3 billion, one of the people said. The other bidder includes Roche Holding AG (SWX:ROG), Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN), Allergan Inc. (NYSE:AGN) and Valeant Pharmaceuticals International, Inc. (TSX:VRX), two of the people said. Non-binding offers are due at the end of the month, one of the people added. According to Bloomberg, representatives for ThromboGenics, Shire, Novartis, Valeant, Allergan and Roche declined to comment.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AGN:US $163.76 USD +0.11

AGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actavis plc $204.28 USD -1.39
Mylan Inc/PA $49.98 USD +0.13
Regeneron Pharmaceuticals Inc $306.10 USD -5.58
Shire PLC 3,189 GBp +43.00
Valeant Pharmaceuticals International Inc C$147.11 CAD -2.27
View Industry Companies
 

Industry Analysis

AGN

Industry Average

Valuation AGN Industry Range
Price/Earnings 38.9x
Price/Sales 7.7x
Price/Book 7.5x
Price/Cash Flow 44.4x
TEV/Sales 6.9x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALLERGAN INC, please visit www.allergan.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.